Roivant Sciences (ROIV) Projected to Post Earnings on Monday

Key Points

• Roivant Sciences is expected to release its Q1 2026 earnings on August 11th, with forecasts showing a loss of ($0.23) per share and revenue of $6.92 million.
• In its previous quarterly report, Roivant missed earnings expectations, reporting ($0.31) EPS and revenue of $7.57 million, significantly below analyst estimates of $62.17 million.
• Recent insider activity includes major shareholder Vivek Ramaswamy selling 577,007 shares, and CEO Eric Venker selling 100,000 shares, indicating notable changes in ownership stakes.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) will likely be releasing its Q1 2026 earnings data before the market opens on Monday, August 11th. Analysts expect Roivant Sciences to post earnings of ($0.23) per share and revenue of $6.92 million for the quarter.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings results on Thursday, May 29th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.15). Roivant Sciences had a negative return on equity of 14.76% and a negative net margin of 225.71%. The firm had revenue of $7.57 million for the quarter, compared to analyst estimates of $62.17 million. During the same period last year, the company earned ($0.23) EPS. On average, analysts expect Roivant Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Roivant Sciences Trading Up 0.1%

Shares of Roivant Sciences stock traded up $0.01 on Monday, reaching $11.32. 692,006 shares of the company were exchanged, compared to its average volume of 5,835,307. Roivant Sciences has a one year low of $8.73 and a one year high of $13.06. The company has a market capitalization of $7.69 billion, a price-to-earnings ratio of -45.31 and a beta of 1.15. The company has a 50-day moving average of $11.27 and a 200 day moving average of $10.86.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. HC Wainwright reiterated a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a research report on Wednesday, June 18th. The Goldman Sachs Group upgraded Roivant Sciences to a "strong-buy" rating and set a $19.00 price objective on the stock in a research report on Thursday, July 10th.

Insider Activity

In related news, major shareholder Vivek Ramaswamy sold 577,007 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $11.46, for a total value of $6,612,500.22. Following the completion of the transaction, the insider owned 37,284,108 shares in the company, valued at $427,275,877.68. This trade represents a 1.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Eric Venker sold 100,000 shares of the firm's stock in a transaction that occurred on Monday, July 21st. The shares were sold at an average price of $11.52, for a total transaction of $1,152,000.00. Following the completion of the transaction, the chief executive officer owned 1,462,223 shares of the company's stock, valued at approximately $16,844,808.96. This trade represents a 6.40% decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,464,462 shares of company stock worth $39,228,856 over the last ninety days. 10.80% of the stock is currently owned by insiders.

Institutional Trading of Roivant Sciences

An institutional investor recently raised its position in Roivant Sciences stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 1.4% in the first quarter, according to its most recent filing with the SEC. The firm owned 2,445,807 shares of the company's stock after purchasing an additional 34,341 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 0.34% of Roivant Sciences worth $24,678,000 at the end of the most recent quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.